Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIC-1911 and Osimertinib in Advanced EGFR-mutated NSCLC
NCT05489731Phase 1Unknown
- Sponsor
- JS InnoPharm
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAS-119 in non-small cell lung cancer (NSCLC), sponsored by JS InnoPharm. Status: unknown.
02
Drugs
TAS-119
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05489731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489731.